✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Selumetinib sulfateis the generic ingredient in one branded drug marketed by Astrazeneca and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.
Selumetinib sulfate has one hundred and fifty-eight patent family members in thirty-nine countries.
One supplier is listed for this compound.
Recent Clinical Trials for selumetinib sulfate
Identify potential brand extensions & 505(b)(2) entrants
|National Cancer Institute (NCI)||Phase 3|
|Sarcoma Alliance for Research through Collaboration||Phase 2|
|United States Department of Defense||Phase 2|
Pharmacology for selumetinib sulfate
|Drug Class||Kinase Inhibitor |
|Mechanism of Action|| Mitogen-Activated Protein Kinase Kinase 1 Inhibitors |
Mitogen-Activated Protein Kinase Kinase 2 Inhibitors
|Country||Patent Number||Title||Estimated Expiration|
|Russian Federation||2004127926||N3-АЛКИЛИРОВАННЫЕ БЕНЗИМИДАЗОЛЬНЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ MEK||See Plans and Pricing|
|Ukraine||93531||НОВИЙ ГІДРОСУЛЬФАТ[НОВЫЙ ГИДРОСУЛЬФАТ (NOVEL HYDROGEN SULFATE SALT)||See Plans and Pricing|
|South Korea||20040094786||See Plans and Pricing|
|Ecuador||SP088597||SAL DE SULFATO DE HIDRÓGENO NOVEDOSA||See Plans and Pricing|
|Hungary||E025767||See Plans and Pricing|
|>Country||>Patent Number||>Title||>Estimated Expiration|
|Patent Number||Supplementary Protection Certificate||SPC Country||SPC Expiration||SPC Description|
|1482932||334 8-2019||Slovakia||See Plans and Pricing||PRODUCT NAME: BINIMETINIB VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/18/1315 20180924|
|1968948||301139||Netherlands||See Plans and Pricing||PRODUCT NAME: SELUMETINIBWATERSTOFSULFAAT, DESGEWENST IN WATERVRIJE VORM OF IN DE VORM VAN EEN SOLVAAT; REGISTRATION NO/DATE: EU/1/21/1552 20210619|
|1968948||CA 2021 00044||Denmark||See Plans and Pricing||PRODUCT NAME: SELUMETINIB, INKLUSIV FARMACEUTISK ACCEPTABLE SALTE (ISAER HYDROGENSULFAT), ESTRE, SOLVATER OG ENANTIOMERE DERAF; REG. NO/DATE: EU/1/21/1552 20210619|
|1482932||C20190010 00281||Estonia||See Plans and Pricing||PRODUCT NAME: BINIMETINIIB;REG NO/DATE: EU/1/18/1315 24.09.2018|
|1482932||C 2019 008||Romania||See Plans and Pricing||PRODUCT NAME: BINIMETINIB; NATIONAL AUTHORISATION NUMBER: EU/1/18/1315; DATE OF NATIONAL AUTHORISATION: 20180920; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1315; DATE OF FIRST AUTHORISATION IN EEA: 20180920|
|>Patent Number||>Supplementary Protection Certificate||>SPC Country||>SPC Expiration||>SPC Description|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.